-
公开(公告)号:US20160280783A1
公开(公告)日:2016-09-29
申请号:US15180879
申请日:2016-06-13
申请人: Joy GHOSH , Mark Anthony RUTZ , Kathrin Ulrike TISSOT-DAGUETTE , Igor SPLAWSKI , Michael ROGUSKA
发明人: Joy GHOSH , Mark Anthony RUTZ , Kathrin Ulrike TISSOT-DAGUETTE , Igor SPLAWSKI , Michael ROGUSKA
IPC分类号: C07K16/26 , A61K39/395 , C07K16/22 , A61K45/06
CPC分类号: C07K16/26 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/22 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
摘要翻译: 本发明涉及抑制EPO的组合物和方法。 本发明提供了结合EPO并能够抑制EPO依赖性细胞增殖和/或EPO依赖性细胞信号传导的抗体及其抗原结合片段。
-
公开(公告)号:US20140199306A1
公开(公告)日:2014-07-17
申请号:US14095910
申请日:2013-12-03
申请人: Joy GHOSH , Mark Anthony RUTZ , Katrin Ulrike TISSOT-DAGUETTE , Igor SPLAWSKI , Michael ROGUSKA
发明人: Joy GHOSH , Mark Anthony RUTZ , Katrin Ulrike TISSOT-DAGUETTE , Igor SPLAWSKI , Michael ROGUSKA
IPC分类号: C07K16/26
CPC分类号: C07K16/26 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/22 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
摘要翻译: 本发明涉及抑制EPO的组合物和方法。 本发明提供了结合EPO并能够抑制EPO依赖性细胞增殖和/或EPO依赖性细胞信号传导的抗体及其抗原结合片段。
-
公开(公告)号:US20160031975A1
公开(公告)日:2016-02-04
申请号:US14698039
申请日:2015-04-28
申请人: Beate DIEFENBACH-STREIBER , Adina EBERTH , Braydon Charles GUILD , Yong-In KIM , Michael ROGUSKA , Igor SPLAWSKI
发明人: Beate DIEFENBACH-STREIBER , Adina EBERTH , Braydon Charles GUILD , Yong-In KIM , Michael ROGUSKA , Igor SPLAWSKI
IPC分类号: C07K16/18
CPC分类号: C07K16/18 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92
摘要: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
-
4.
公开(公告)号:US20130064836A1
公开(公告)日:2013-03-14
申请号:US13557562
申请日:2012-07-25
申请人: Beate DIEFENBACH-STREIBER , Adina EBERTH , Braydon Charles GUILD , Yong-In KIM , Michael ROGUSKA , Igor SPLAWSKI
发明人: Beate DIEFENBACH-STREIBER , Adina EBERTH , Braydon Charles GUILD , Yong-In KIM , Michael ROGUSKA , Igor SPLAWSKI
IPC分类号: A61K39/395 , C12N5/10 , C07K16/18 , C07K16/46 , A61P25/28 , A61P27/02 , A61P11/06 , A61P19/02 , A61P1/00 , A61P17/06 , C12N15/85 , C12N15/13
CPC分类号: C07K16/18 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92
摘要: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
摘要翻译: 本发明涉及靶向补体蛋白C5的抗体及其使用方法。
-
公开(公告)号:US20130022615A1
公开(公告)日:2013-01-24
申请号:US13535612
申请日:2012-06-28
申请人: Beate DIEFENBACH-STREIBER , Adina EBERTH , Braydon Charles GUILD , Yong-In KIM , Michael ROGUSKA , Igor SPLAWSKI
发明人: Beate DIEFENBACH-STREIBER , Adina EBERTH , Braydon Charles GUILD , Yong-In KIM , Michael ROGUSKA , Igor SPLAWSKI
IPC分类号: A61K39/395 , A61P27/02
CPC分类号: C07K16/18 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92
摘要: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
-
公开(公告)号:US20160297854A1
公开(公告)日:2016-10-13
申请号:US15186025
申请日:2016-06-17
申请人: Joy GHOSH , Michael ROGUSKA , Andrew Anh NGUYEN , Thomas PIETZONKA , Matthias MACHACEK , Andrei GOLOSOV
发明人: Joy GHOSH , Michael ROGUSKA , Andrew Anh NGUYEN , Thomas PIETZONKA , Matthias MACHACEK , Andrei GOLOSOV
IPC分类号: C07K14/00 , A61K31/713 , A61K47/48 , C07K16/22 , C12N15/115
CPC分类号: C07K14/00 , A61K31/713 , A61K38/00 , A61K39/3955 , A61K47/42 , A61K47/64 , C07K14/4718 , C07K16/22 , C07K2317/51 , C07K2317/515 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C07K2317/94 , C07K2319/20 , C07K2319/31 , C07K2319/33 , C12N15/115 , C12N2310/16 , C12N2310/3513 , C12N2320/32
摘要: The invention relates, in part, to compositions and methods that utilize a peptide tag that binds to hemagglutanin (HA). The HA tag can be linked to a molecule such as a protein or nucleic acid which, when administered to the eye, results in an increase in ocular half-life and/or mean residence time, and or a decrease in ocular clearance of the protein or nucleic acid. The invention also encompasses methods for treating ocular disease, including retinal vascular disease, by administering a protein or nucleic acid linked to an HA peptide tag.
摘要翻译: 本发明部分地涉及利用结合血凝素(HA)的肽标签的组合物和方法。 HA标签可以连接到分子,例如蛋白质或核酸,当被施用于眼睛时,导致眼半衰期和/或平均停留时间的增加和/或蛋白质的眼清除率的降低 或核酸。 本发明还包括通过施用与HA肽标签连接的蛋白质或核酸来治疗眼部疾病(包括视网膜血管疾病)的方法。
-
公开(公告)号:US20140186350A1
公开(公告)日:2014-07-03
申请号:US14109426
申请日:2013-12-17
申请人: Joy GHOSH , Michael ROGUSKA , Andrew Anh NGUYEN , Thomas PIETZONKA , Stephen POOR , Matthais MACHACEK , Chad BIGELOW
发明人: Joy GHOSH , Michael ROGUSKA , Andrew Anh NGUYEN , Thomas PIETZONKA , Stephen POOR , Matthais MACHACEK , Chad BIGELOW
IPC分类号: A61K47/42 , A61K39/395
CPC分类号: C07K14/00 , A61K31/713 , A61K38/00 , A61K39/3955 , A61K47/42 , A61K47/64 , C07K14/4718 , C07K16/22 , C07K2317/51 , C07K2317/515 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C07K2317/94 , C07K2319/20 , C07K2319/31 , C07K2319/33 , C12N15/115 , C12N2310/16 , C12N2310/3513 , C12N2320/32
摘要: The invention relates, in part, to compositions and methods that utilize a peptide tag that binds to hemagglutanin (HA). The HA tag can be linked to a molecule such as a protein or nucleic acid which, when administered to the eye, results in an increase in ocular half-life and/or mean residence time, and or a decrease in ocular clearance of the protein or nucleic acid. The invention also encompasses methods for treating ocular disease, including retinal vascular disease, by administering a protein or nucleic acid linked to an HA peptide tag.
摘要翻译: 本发明部分地涉及利用结合血凝素(HA)的肽标签的组合物和方法。 HA标签可以连接到分子,例如蛋白质或核酸,当被施用于眼睛时,导致眼半衰期和/或平均停留时间的增加和/或蛋白质的眼清除率的降低 或核酸。 本发明还包括通过施用与HA肽标签连接的蛋白质或核酸来治疗眼部疾病(包括视网膜血管疾病)的方法。
-
公开(公告)号:US20170290876A1
公开(公告)日:2017-10-12
申请号:US15315626
申请日:2015-06-24
申请人: Joy GHOSH , Michael ROGUSKA , Andrew Anh NGUYEN , Thomas PIETZONKA , Stephen Hedrick POOR , Matthias MACHACEK , Chad Eric BIGELOW
发明人: Joy GHOSH , Michael ROGUSKA , Andrew Anh NGUYEN , Thomas PIETZONKA , Stephen Hedrick POOR , Matthias MACHACEK , Chad Eric BIGELOW
IPC分类号: A61K38/00 , A61K31/7105 , A61K31/711 , A61K38/02 , A61K45/06
CPC分类号: A61K38/005 , A61K31/7105 , A61K31/711 , A61K38/02 , A61K45/06 , A61K2121/00 , C07K2319/31 , C12N15/62
摘要: The present invention is based, in part, on the discovery of peptide tags that increase the half-life and/or mean residence time of proteins or nucleic acids in the eye. In certain aspects the invention peptide tags increase the half-life and/or mean residence time of antibodies and antigen binding fragments, therapeutic proteins, protein receptors, DARPins and/or aptamers in the eye.
-
公开(公告)号:US20170202981A1
公开(公告)日:2017-07-20
申请号:US15321025
申请日:2015-06-24
摘要: The invention provides compositions for rendering a vitreous cavity visible during a surgical procedure to alleviate a structural disorder caused by the vitreous in an eye, and methods of using the compositions. The compositions are vitreous delineating agents that comprise a hyaluronan binding peptide linked to an optically detectable moiety. Such compositions can be in a formulation that may be a solution, a suspension, or an emulsion, and would be injected into the vitreous shortly prior to use. The composition may additionally contain a therapeutic agent, a diagnostic agent, or a chemosensing material, in use, the composition marks or delineates the vitreous by binding preferentially to the hyaluronan that permeates the vitreous humor and binding little or not at all to surrounding tissues such as the retina. The interface between the labelled vitreous humor and the non-labelled surrounding vital tissues produces a visible signal, thereby allowing a surgeon to clearly visualize the entire vitreous cavity and distinguish it from vital ocular structures. Use of the method improves the accuracy and safety of a vitrectomy and thus prevents suboptimal outcomes or the need for repeated procedures. The compositions comprising chemosensing material are useful as long-lasting biosensors, which when used in the vitreous enable repetitive, non-invasive, in vivo measurements of metabolites or pharmacologic agents in the vitreous of animals or humans.
-
10.
公开(公告)号:US20090269302A1
公开(公告)日:2009-10-29
申请号:US12392614
申请日:2009-02-25
申请人: Jochen SALFELD , Michael ROGUSKA , Michael PASKIND , Subhashis BANERJEE , Daniel TRACEY , Michael WHITE , Zehra KAYMAKCALAN , Boris LABKOVSKY , Paul SAKORAFAS , Geertruida M. VELDMAN , Amy VENTURINI , Angela WIDOM , Stuart FRIEDRICH , Nicholas W. WARNE , Angela MYLES , John Gawain ELVIN , Alexander Robert DUNCAN , Elaine Joy DERBYSHIRE , Sara CARMEN , Stephen SMITH , Thor Las HOLTET , Sarah Leila DU FOU
发明人: Jochen SALFELD , Michael ROGUSKA , Michael PASKIND , Subhashis BANERJEE , Daniel TRACEY , Michael WHITE , Zehra KAYMAKCALAN , Boris LABKOVSKY , Paul SAKORAFAS , Geertruida M. VELDMAN , Amy VENTURINI , Angela WIDOM , Stuart FRIEDRICH , Nicholas W. WARNE , Angela MYLES , John Gawain ELVIN , Alexander Robert DUNCAN , Elaine Joy DERBYSHIRE , Sara CARMEN , Stephen SMITH , Thor Las HOLTET , Sarah Leila DU FOU
CPC分类号: C07K16/244 , A61K9/0019 , A61K38/208 , A61K39/00 , A61K39/3955 , A61K39/39591 , A61K45/06 , A61K47/20 , A61K47/22 , A61K47/26 , A61K2039/505 , C07K14/5434 , C07K16/00 , C07K16/18 , C07K2317/21 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/94 , Y10S514/863 , Y10S514/885 , Y10S514/886
摘要: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
摘要翻译: 公开了特异性结合人白细胞介素-12(hIL-12)的人抗体,优选重组人抗体。 优选的抗体对hIL-12具有高亲和力,并在体外和体内中和hIL-12活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 本发明的抗体或抗体部分可用于检测hIL-12和抑制hIL-12活性,例如在患有hIL-12活性有害的病症的人类受试者中。 用于表达本发明的重组人抗体的核酸,载体和宿主细胞以及合成重组人抗体的方法也包括在本发明中。
-
-
-
-
-
-
-
-
-